Navigation Links
French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec
Date:9/1/2010

French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec -- CLERMONT-FERRAND, France, September 1, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Acquisitions, Mergers and Takeovers, New Products & Services Click to view news release full screen  

French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec

 

CLERMONT-FERRAND, France, September 1, 2010 /PRNewswire/ -- Laboratoires Thea, the leading independent ophthalmic group in Europe, completes its innovative product range with the announcement of the final acquisition of Mydriasert(R). Mydriasert(R), the 1st mydriatic ophthalmic insert, is indicated for dilated fundus examination (DFE) or cataract surgery, the most widely implemented surgical procedure. Regarding cataract surgery, the market represents close to 300 000 procedures in the UK and Ireland and 3 million in Europe each year.

"This acquisition represents a significant addition to our product range and is completely in line with our strategy to become a leading provider of ophthalmic products. Our goal is to meet the needs of ophthalmologists in all major therapeutic classes so that we can be their daily partners, whatever their type of practice, and notably in ocular surgery," according to Laboratoires Thea COO Jean-Frederic Chibret. The agreement with Carl Zeiss Meditec includes the acquisition of the production site of Mydriasert(R) located in La Rochelle, France along with relevant staff. Mydriasert(R) is already commercialized in five European countries. Thanks to this agreement, Carl Zeiss Meditec will continue to concentrate on its core activities. Laboratoires Thea will develop sales through their subsidiaries and distributors.

Mydriasert(R) provides a genuine alternative to the mydriatic eye drops that are commonly used for mydriasis.

Mydriasert(R) allows one to obtain an effective and stable mydriasis with just one simple medical act which helps to avoid repeat installations of different mydriatic eye drops either for surgical procedures or diagnostic purposes.

In comparison to traditional mydriatic eye drops, Mydriasert(R) allows for fewer nursing procedures, this in turn helps to free up nursing time, reduce the risk of human errors and allows healthcare staff to spend more time with their patients[1]. The insert contains neither preservatives nor solvents.

This device, shaped like an oblong tablet, is applied beneath the eyelid and disperses both phenylephrin hydrochlorid and tropicamide, whose mechanisms of action are synergistic. Indeed, the alpha-sympathomimetic activity of phenylephrin induces an increase in pupil diameter, while the anti-cholinergic activity of tropicamide prevents the iris from contracting.

Heading towards new technologies

The acquisition of this French technology offers Thea new research and development opportunities. The system is comprised of a sterile, bio-compatible and porous matrix containing the ingredients which are gradually released into the lower conjunctival sac of the eye. The clinical situations in which it may be interesting to control the quantities of active ingredients administered onto the ocular surface are indeed quite numerous.

About Laboratoires Thea

Laboratoires Thea is the leading independent ophthalmic group in Europe. Founded in 1994, the company is a family business built on the heritage of over 150 years experience of the Chibret Family in Ophthalmology.

Today, Laboratoires Thea is ranked 3rd in France, 6th in Europe and 7th worldwide in the field of Ophthalmology. The company is present in 65 countries, owns 11 subsidiaries in Europe and had a turnover of EUR 171 million in 2009.[2]

References

---------------------------------

[1] Korobelnik JF, Tavera C, Renaud-Rougier MB, El Meski S, Colin J.; The Mydriasert insert: an alternative to eye drops for preangiographic mydriasis; Le Journal Francais d'Ophtalmologie 2004 Oct;27(8):897-902

[2] http://www.laboratoires-thea.com/ Media contact: Burson-Marsteller France Linda.pavy@bm.com Tel. +33-1-41-86-76-26 - Cell: +33-6-07-59-43-95
'/>"/>

SOURCE Laboratoires Thea
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
4. ResMed Acquires Laboratoires Narval
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
7. U.S. Preventive Medicine Acquires Specialty Disease Management
8. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
9. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
10. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
11. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... Definitive Financing Commitment Term Sheet (the "Definitive Financing") ... group of the Company,s stockholders, who are referred ... in a Form 8-K filed with the Securities ...
(Date:3/23/2017)... , March 23, 2017 Mosaic Life Care, based in St. ... registration process across its network of 58 clinics, located in 22 cities, and its ... and innovative ways to improve the delivery of health care to its patients, including ... ... Mosaic Life Care St. Joseph Medical Center ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... In just ... EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone ... with nearly 2,000 consumers (and counting) already backing the campaign. , “We ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate themselves on ... cultural practices, goods, services, and societal issues tend to appreciate and love the "Informed" ... practice of utilizing running events for causes around the world. , Running ...
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
(Date:3/23/2017)... , ... March 23, 2017 , ... A recent report ... entry into teacher preparation programs. The NCTQ report suggests, based on a review of ... would significantly improve teacher quality in the U.S. It argues that this higher bar ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
Breaking Medicine News(10 mins):